The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 3, 2010, Pages 263-271

  Gillespie, Paddy ^a   O'Shea, Eamon ^a   Murphy, Andrew W ^a   Byrne, Mary C ^a   Byrne, Molly ^a,b   Smith, Susan M ^c   Cupples, Margaret E ^d  

^a Department of Economics ^*  (United Kingdom)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Coronary heart disease; Cost effectiveness analysis; General practice; Secondary prevention

Indexed keywords

CLINICAL PRACTICES; CONFIDENCE INTERVAL; CONTROL STRATEGIES; CORONARY HEART DISEASE; COST SAVING; COST-EFFECTIVENESS ANALYSIS; DECISION MAKERS; GENERAL PRACTICE; HEALTH-CARE SYSTEM; HEART DISEASE; INCREMENTAL COST; INTERVENTION STRATEGY; IRELAND; LIFETIME COSTS; PATIENT CARE; PROBABILISTIC MODELS; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION;

CARDIOLOGY; COST EFFECTIVENESS; COSTS; DECISION MAKING; HEART; SPHERES;

COST BENEFIT ANALYSIS;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GENERAL PRACTICE; HUMAN; IRELAND; ISCHEMIC HEART DISEASE; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; QUESTIONNAIRE;

CORONARY DISEASE; COST-BENEFIT ANALYSIS; FAMILY PRACTICE; HUMANS; IRELAND; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SECONDARY PREVENTION;

EID: 78049444223     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310000358     Document Type: Article

References (25)

1. Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2007;7:605-611.
2. Brazier JE,Roberts J. Estimating a preference-based index from the SF-12. Med Care. 2004;42:851-859.
3. Campbell MK, Elbourne DR, Altman DG, et al. CONSORT statement: Extension to cluster randomised trials. BMJ. 2004;328:702-708.
4. Central Bank of Ireland. Dublin (www.centralbanK.ie). (Accessed June 2008)
5. Central Statistics Office. Dublin (www.cso.ie). (Accessed June 2008)
6. Clark AM, Hartling L, Vandermeer B, McAlister FA. Metaanalysis: Secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659-672.
7. Cupples ME, Byrne MC, Smith SM, Leathem C, Murphy AW. Secondary prevention of cardiovascular disease in different primary healthcare systems, with and without pay-forperformance. Heart. 2008;94:1594-1600.
8. D'Agostino RB, Russell M, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from The Framingham Study. Am Heart J. 2000;139:272-281.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-1610.
10. Department of Health and Children. The National Heartwatch Programme: Clinical report - March 2003 to December 2005. Dublin; 2006.
11. Drummond MF, Sculpher MJ, Torrance GW, O'Brien J, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press;2005.
12. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press; 2007.
13. Hardin JW, Hilbe JM. Generalised estimating equations. London: Chapman and Hall/CRC Press; 2003.
14. Johnston K, Gray A, Moher M, et al. Reporting the costeffectiveness of interventions with nonsignificant effect differences: Example from the a trial of secondary prevention of heart disease. Int J Technol Assess Health Care. 2003;19:476-489.
15. Ketola E, Laatikainen T, Vartianinen E. Evaluating risk for cardiovascular diseases -vain or value? How do different cardiovascular risk scores act in real life. Eur J Public Health. 2010;20:107-112.
16. Lacey EA,Walters SJ.Continuing inequality: Gender and social class influences on self perceived health after a heart attacK. J Epidemiol Community Health. 2003;57:622-627.
17. Manca A, Hawkins N, Sculpher M. Estimating mean QALYs in trial based cost effectiveness analysis: The importance of controlling for baseline utility. Health Econ. 2005;14:487-496.
18. Murphy AW, Cupples ME, Smith S, et al. Secondary prevention of heart disease in general practice: A cluster randomised controlled trial of tailored practice and patient care plans. BMJ. 2009;339:b4220.
19. Netten A, Curtis J. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit. University of Kent; 2006.
20. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004. www.nice.org.uk/page.aspx?o=201974 (reference 0515).
21. O'Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness of personal health education in primary care for people with angina in the Greater Belfast area of Northern Ireland. J Epidemiol Community Health. 1996;50:538-540.
22. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: Follow up of a randomised controlled trial. BMJ. 2005;330: 707.
23. Robinson M, Palmer S, Sculpher M, et al. Cost effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: Systematic reviewand decision-analytical modelling. Health Technol Assess. 2005;9:iii-iv, ix-xi, 1-158.
24. Turner DA, Paul SK, Stone M, et al. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care. Heart. 2008;94:1601-1606.
25. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.